Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04555785 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Enhancement of the Haemostatic Effect of Platelets in the Presence of High Normal Concentrations of Von Willebrand Factor

Study acronym: Will-Plate
StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

  1. Re-verified, no change to tracked fieldsv10
  2. Primary completion date: Nov 2025 to Nov 2027
    • Study completion date: Nov 2026 to Nov 2028
    v9
  3. Primary completion date: Mar 2024 to Nov 2025
    • Study completion date: Mar 2025 to Nov 2026
    v8
  4. Re-verified, no change to tracked fieldsv7
  5. Start date: Feb 3, 2022 to Apr 1, 2022
    • Primary completion date: Jan 2024 to Mar 2024
    • Study completion date: Jan 2025 to Mar 2025
    v6
Show 4 earlier versionsHide 4 earlier versions
  1. Trial status: Not Yet Recruiting to Recruitingv5 Show 4 more changesShow less
    • Primary completion date: Dec 2024 to Jan 2024
    • Study completion date: Dec 2025 to Jan 2025
    • Start date changed from estimate of Jan 24, 2022 to Feb 3, 2022
    • Site details revised
  2. Primary completion date: Oct 2023 to Dec 2024
    • Start date: Nov 2021 to Jan 24, 2022
    • Study completion date: Oct 2024 to Dec 2025
    v4
  3. Start date: May 2021 to Nov 2021
    • Primary completion date: Apr 2023 to Oct 2023
    • Study completion date: Apr 2024 to Oct 2024
    v3
  4. Start date: Nov 2020 to May 2021
    • Primary completion date: Oct 2022 to Apr 2023
    • Study completion date: Apr 2023 to Apr 2024
    v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Assessment of high-normal dosage of Wilate ® compared to placebo administered in combination with platelets to assess reduction of amount of blood loss, need of transfusion products and outcome (length of stay, mortality) in patients with bleeding in comparison.
Trial Details
NCT Number NCT04555785
Lead Sponsor University Hospital, Basel, Switzerland
Conditions
(from sponsor)		 Bleeding
Related terms Hemorrhage
Enrollment 120 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov